Neural Biological Materials Biomarker Assay
Neural biological materials, such as cerebrospinal fluid (CSF) and blood, are commonly used for detecting biomarkers of neurological diseases. The biomarkers can be used to diagnose, predict disease progression, and evaluate treatment efficacy. However, the detection of these biomarkers is challenging due to their low concentrations and the complexity of the biological matrix. To overcome these challenges, Creative Biolabs has developed a Neural Biological Materials Biomarker Assay Service, which utilizes state-of-the-art technologies to accurately detect and quantify neural biomarkers in various sample types.
Neuroinflammatory Biomarkers Assay
Neuroinflammation is a common feature of many neurological diseases, such as Alzheimer's disease, Parkinson's disease and multiple sclerosis. Creative Biolabs' neuroinflammation biomarker assay can detect various biomarkers related to neuroinflammation, including cytokines, chemokines, and growth factors. We utilize advanced immunoassay techniques such as ELISA, multiplex assays, and bead-based immunoassays to detect neuroinflammatory biomarkers. In addition, the assay can be tailored to detect specific biomarkers of interest in various sample types, including cerebrospinal fluid, plasma, and serum.
Neurodegeneration Biomarkers Assay
Neurodegeneration, the progressive loss of neuronal structure or function, is a hallmark of various neurological disorders such as Alzheimer's, Parkinson's and Huntington's disease. Creative Biolabs' Neurodegeneration Biomarker Assay can detect various biomarkers associated with neurodegeneration, including amyloid-beta, tau, alpha-synuclein, and huntingtin. These biomarkers are critical for understanding the underlying mechanisms of neurodegeneration and developing new treatments.
Fig.1 Cerebrospinal and plasma biomarkers analysis in Alzheimer's disease (left). Mouse spinal cord samples analysis (right).(Palmqvist, 2019)
Sample Types
Accurate and reliable biomarker assays require high-quality samples. Creative Biolabs offers assays for a range of sample types, including cerebrospinal fluid (CSF), blood, plasma, and brain tissue. Our assays are optimized for each sample type to provide the most accurate results possible. We can handle various sample volumes and types, from small animal models to large clinical studies. Moreover, the assay can be customized to detect specific biomarkers of interest in different sample types, depending on the research questions.
Applications
Our Neural Biological Materials Biomarker Assay Service has a wide range of applications, including:
- Identification and validation of biomarkers for neurological diseases
- Monitoring disease progression and treatment response
- Preclinical and clinical drug development
- Clinical trial support
Our assay service is customizable, allowing researchers to select the biomarkers and sample types that best suit their research needs. Our team of experienced scientists is dedicated to providing high-quality results and excellent customer service.
Our Advantages
At Creative Biolabs, we pride ourselves on our cutting-edge technology, experienced scientists, and commitment to quality. Our Neural Biological Materials Biomarker Assay Service offers several advantages:
- Customizable assays tailored to specific research needs
- State-of-the-art techniques for accurate and reliable results
- Experienced scientists dedicated to providing high-quality service and support
- Competitive pricing and timely delivery of results
- High-quality samples for reliable and reproducible results
In summary, Creative Biolabs offers a comprehensive Neural Biological Materials Biomarker Assay Service that provides accurate and reliable measurements of neuroinflammatory and neurodegeneration biomarkers in a variety of sample types. Our service has a wide range of applications and is backed by our commitment to quality and customer satisfaction.
Get in touch with us today to find out more about our neural biomarker assay services.
Reference
- Palmqvist, Sebastian, et al. "Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease." EMBO molecular medicine 11.12 (2019): e11170.
